Ataluren is indicated for the treatment of DMD resulting from a nonsense mutation in the dystrophin gene, in ambulatory patients aged 5 years and older. The presence of a nonsense mutation in the dystrophin gene should be determined by genetic testing.
|18/11/2014||23/12/2014||Full Pharmacoeconomic Evaluation Recommended.|
|29/10/2015||29/04/2016||Reimbursement Not Recommended|
The HSE has approved reimbursement following confidential price negotiations; May 2019